ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme .

http://www.news-medical.net/news/20130730/ImmunoCellular-initiates-ICT-121-phase-I-trial-in-patients-with-recurrent-glioblastoma-multiforme.aspx